Research Article

[Retracted] Time Intervals between Double Primary Breast and Ovarian Cancers and Survival Outcomes of Patients with Both Cancers: A SEER Database Analysis

Table 1

Demographic and clinicopathological characteristics of patients with primary BC and primary OC stratified by tumor sequence and time intervals between both cancers.

VariablesBC to OC
Group 1
Synchronous
Group 2
OC to BC
Group 3
valueOverall

Total, (%)2,929 (58.9%)680 (13.7%)1,366 (27.5%)4,975
Age (median, range) at BC diagnosis59 (23–93)64 (28–98)66 (22–97)<0.0562 (22–98)
Age (median, range) at OC diagnosis67 (25–98)64 (28–98)57 (10–90)<0.0564 (10–98)
Race0.008
 White2,372 (81.0%)526 (77.4%)1,118 (81.8%)4,016 (80.7%)
 Black154 (5.3%)61 (9.0%)76 (5.9%)291 (5.8%)
 Hispanic213 (7.3%)52 (7.6%)84 (6.1%)349 (7.0%)
 Asian/Pacific islander176 (6.0%)35 (5.1%)84 (6.1%)295 (5.9%)
 Other14 (0.5%)6 (0.9%)4 (0.3%)24 (0.5%)
OC distribution by year<0.001
 1973–198294 (3.2%)67(9.9%)245 (17.9%)406 (8.2%)
 1983–1992349 (11.9%)84(12.4%)267 (19.5%)700 (14.1%)
 1993–2002704 (24.0%)172 (25.3%)414 (30.3%)1,290 (25.9%)
 2003–20151,782 (60.8%)357 (52.5%)440 (32.2%)2,579 (51.8%)
BC distribution by year<0.001
 1973–1982439 (15.0%)67 (9.9%)57 (4.2%)563 (11.3%)
 1983–1992613 (20.9%)85 (12.5%)164 (12.0%)862 (17.3%)
 1993–20021,099 (37.5%)171 (25.1%)285 (20.9%)1,555 (31.3%)
 2003–2015778 (26.6%)357 (52.5%)860 (63.0%)1,995 (40.1%)
OC grade<0.001
 Grade I99 (3.4%)46 (6.8%)156 (11.4%)301 (6.1%)
 Grade II304 (10.4%)78 (11.5%)241 (17.6%)623 (12.5%)
 Grade III1,013 (34.6%)201 (29.6%)432 (31.6%)1,646 (33.1%)
 Grade IV435 (14.9%)67 (9.9%)127 (9.3%)629 (12.6%)
 Unknown1,078 (36.8%)288 (42.4%)410 (30.0%)1,776 (35.7%)
OC stage (2004–2015)1663339382<0.0012,384
 I238 (14.3%)71 (20.9%)133 (34.8%)442 (18.5%)
 II144 (8.7%)26 (7.7%)49 (12.8%)219 (9.2%)
 III658 (39.6%)120 (35.4%)120 (31.4%)898 (37.7%)
 IV436 (26.2%)83 (24.5%)62 (16.2%)581 (24.4%)
 Unknown187 (11.2%)39 (11.5%)18 (4.7%)244 (10.2%)
OC pathologic type<0.001
 Serous1,354 (46.2%)294 (43.2%)510 (37.3%)2,158 (43.4%)
 Mucinous109 (3.7%)38 (5.6%)155 (11.3%)302 (6.1%)
 Clear cell111(3.8%)28 (4.1%)85 (6.2%)224 (4.5%)
 Endometrioid193 (6.6%)49 (7.2%)227 (16.6%)469 (9.4%)
 Other1,162 (39.7%)271 (39.9%)389 (28.5%)1,822 (36.6%)
BC grade<0.001
 Grade I364 (12.4%)102 (15.0%)215 (15.7%)681 (13.7%)
 Grade II715 (24.4%)172 (25.3%)451 (33.0%)1,338 (26.9%)
 Grade III883 (30.1%)197 (29.0%)435 (31.8%)1,515 (30.5%)
 Grade IV83 (2.8%)11 (1.6%)16 (1.2%)110 (2.2%)
 Unknown884 (30.2%)198 (29.1%)249 (18.2%)1,331 (26.8%)
BC stage (1988–2015)#2,2185661,235<0.0014,019
 I1,100 (49.6%)191 (33.7%)625 (50.6%)1,916 (47.7%)
 II710 (32.0%)157 (27.7%)343 (27.8%)1,210 (30.1%)
 III214 (9.6%)53 (9.4%)109 (8.8%)376 (9.4%)
 IV34 (1.5%)69 (12.2%)54 (4.4%)157 (3.9%)
 Other160 (7.2%)96 (17.0%)104 (8.4%)360 (9.0%)
BC pathologic type0.096
 Infiltrating ductal carcinoma2,091 (71.4%)458 (67.4%)976 (71.4%)3,525 (70.9%)
 Other838 (28.6%)222 (32.6%)390 (28.6%)1,450 (29.1%)
 Interval (median, range), in months75 (7–499)73 (7–496)60 (0–499)

Note: Ovarian cancer stage derived from AJCC 6th Stage (2004+); #breast cancer stage adjusted for AJCC 6th Stage (1988+); OC: ovarian cancer; BC: breast cancer.